Cyprotex expands U.K. facility into Biohub
BioHub will provide Cyprotex with additional capacity for laboratories and office space. The laboratories include fully-equipped cell culture facilities and radiochemical handling capabilities.
This expansion follows highly encouraging growth figures for the business in the first six months of the year, with a revenue increase of 22.3% in the first quarter compared to the year-ago period and a record half-year operating profit of $509,000. Performance remains strong across all geographical markets and main service operations of high throughput ADME, customized ADME and toxicology.